The market experiences a robust level of mergers and acquisitions (M&A), as pharmaceutical giants actively acquire smaller biotech firms to access innovative pipelines and expand their therapeutic portfolios. Recent trends include consolidation in the specialty drug and biologics segments, as well as acquisitions to strengthen manufacturing capabilities and geographic presence. Strategic partnerships between pharmaceutical companies and technology firms are also on the rise to leverage AI and big data for drug discovery and patient care. The Asia-Pacific market is one of the promising regional markets for generic drugs worldwide. The APAC market held the second-largest worldwide market share in 2024, falling right behind North America.
Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report. Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential. In terms of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies & drug stores, and online pharmacies.
- Another treatment of note is Alyftrek (deutivacaftor/tezacaftor/vanzacaftor), a new triple-combination treatment for cystic fibrosis that should offer benefits over the current blockbuster treatment for patients who have at least one specific mutation.
- The rising use of prescription drugs in this demographic, particularly for conditions like hypertension and diabetes, is expected to continue driving market growth.
- Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
- This segment is driven by the increasing burden of acute and chronic diseases, rising hospitalization rates, and advancements in specialized treatments such as oncology, critical care, and infectious diseases.
- Furthermore, In 2023, drug spending in nonfederal hospitals decreased by 1.1%, totaling USD 37.1 billion, while expenditures in clinics increased by 15.0% to USD 135.7 billion.
- Factors driving expansion include rising disease burden, improving healthcare infrastructure, and favorable government policies.
Online World Drug Report 2024 – Drug Market Patterns And Trends
In 2022, specialty product growth outpaced traditional product growth, with a 51% share of total non-discounted spend (Figure 1). In the moving annual total (MAT) to January 2023 (MAT January 2023), specialty spend grew by 11.7% while traditional growth grew 7.3% on an invoice price basis. In addition, compared to some other routes of administration (such as injections or intravenous infusions), taking medications orally is generally less invasive and more comfortable for patients. OTC medications are typically regarded as safe when used as prescribed, however, abuse or overuse of them may raise safety issues. Making sure that products are safe for consumers is a continuous problem since certain components may have negative effects or interact with other treatments. The rate of penetration of obesity drugs is estimated to jump from about 1% currently to 10% of the obese population in the next 10 years, reaching a total market of $70 billion.
What Is Driving The Pharmaceutical Drugs Market? Rare Diseases Are Fueling The Pharmaceutical Drug Market’s Growth
The development of wind farms necessitates specialized lubricants to ensure the efficient operation of turbines. For example, Total Eren’s planned 112-megawatt wind farm in San Marcos de Colón, Honduras, underscores the region’s commitment to renewable energy. As Central American countries continue to embrace renewable energy sources, the demand for lubricants tailored to these industries is expected to rise, further contributing to the growth of the lubricant market. The other segment contains critical and life-saving drugs such as oncology, anti-diabetic and cardiovascular drugs and has been instrumental in the dominance of this segment in the global market.
The Germany Drugs Market Trends
Table 2 showsdrug expenditures and the total number of prescriptions from 2017 to2022 for small molecule drugs and biological products. Totalinflation-adjusted expenditures on prescription drugs grew from $522billion in 2017 to $618 billion in 2022, an 18.4 percent increase. Totalprescriptions had a similar percentage point increase, from 8.019billion in 2017 to 9.315 billion in 2022 (a 16.2 percent increase). Theincrease in total expenditures was driven by a 54.6 percent increase inexpenditures on biological products, from $163 billion in 2017 to $252billion in 2022. This pattern is similar to thatfor the broader prescription drug market.9 In contrast, spendingon small molecule drugs remained almost flat during this period, atapproximately $360 billion per year, while the number of prescriptionsincreased 19.2 percent.
What Are The Current Trends And Dynamics In The Global Prescription Drugs Market?
On the other hand, Asia-Pacific is projected to register a reasonably high CAGR throughout the forecast period. The presence of prominent players and rising awareness of chronic disorders are the factors that contribute to the growth of the global prescription drug market. New product launches of the efficient prescription product coupled with orphan drugs and rising demand for the advanced prescription product are the factors that contribute to the global growth of the prescription drugs market. As per our prescription drugs market forecast, the hospital pharmacies accumulated a significant market share in 2021. The high growth in this segment is credited to the stringent policies to sell drugs prescribed from healthcare providers. In addition, hospital pharmacies consists all sorts of drugs that are required to cure every disease.
Generic Drugs Market Analysis By Mordor Intelligence
The category may include medications created by pharmaceutical companies or researchers that were never meant to reach the public. The parenteral route of drug administration is expected to grow at a CAGR of 7.31% over the foracst period. This segment involves delivering medications directly into the body through methods such as injections, infusions, or implantations. North America retains leadership with 33.20% share in 2024, propelled by the statutory reality that generics constitute over 90% of prescriptions yet only 18% of spending. The Federal Trade Commission campaign against “junk patents” threatens to accelerate generic entry for 20 high-value brands, potentially adding USD 5-7 billion in annual U.S. generic revenue by 2027.
Pharmaceutical Market Opportunity: Personalized Medicine
This was owing to the limited number of patient visits to hospitals and low dispersion of prescriptions by healthcare professionals, further lowering the demand and adoption of these drugs. They are one of the main profit-generating activities of organised crime and are estimated to represent around one-fifth of global crime proceeds. The negative impacts of illicit drug markets are multifaceted and far-reaching, which is why they remain a key threat to the security of the European Union and the safety of its citizens. Healthcare leaders gathered at Health Evolution’s 2023 Connect to discuss important topics pertaining to the sector, including the pharmaceutical market’s critical obstacles. Leaders urged CEOs to use new AI technologies, pointing out that recent developments in AI might significantly affect pharmaceutical research and innovation.
Traditionally, innovative medicine growth has occurred most in the years immediately following launch, whereas recent years and the forecast outlook show growth driven by older products. This mix of spending growth between volume-driven growth, and mix-driven changes in the cost of therapy are showing most geographies shifting to more expensive therapies, reflecting the broader availability and patient access to medicines with higher clinical value. The oncology segment is observed to witness the fastest rate of expansion at a CAGR of 6.6% during the forecast period. Cancer is one of the leading causes of mortality globally, and the demand for effective cancer treatments continues to rise.
- The cost-effectiveness of these drugs and the growing adoption of pure generic drugs in developing countries primarily drive the segment’s growth.
- Also, this kind of consistent innovation impels demand for branded drugs, as patients are looking for novel treatments for different diseases.
- Among the other competition categories, the relativepercent of total expenditures was lower than the relative percent ofdrugs represented.
- Additionally, some of the key industry players are focusing on the development of orphan drugs for the treatment of several rare disorders.
- These behaviors collectively boost product turnover, reinforcing the position of cough and cold preparations as a primary driver in the nonprescription market.
- The adoption of these drugs is increasing across the country owing to the higher prevalence of chronic diseases and an increasing number of prescriptions written by healthcare professionals.
Pharmaceutical Market Trends
Cardiovascular therapies retained 22.50% of 2024 revenue on the back of entrenched prescription volumes for antihypertensives, statins, and antithrombotics. Long-cycle consumption fosters predictable demand curves, enabling manufacturers to fine-tune capacity allocation. Branded reference price erosion remains gradual, allowing disciplined generic price management that stabilizes gross margins despite competitive density. Injectables captured 61.50% of revenue in 2024, driven by hospital demand for critical-care antibiotics, oncolytics, and parenteral nutrition. The subsegment exhibits oligopolistic traits because five firms collectively hold 46% share, reflecting high entry barriers stemming from aseptic production and stringent particulate specifications. Notably, 70% of generic injectable lines still fail to reach break-even within three years of launch, highlighting persistent profitability hurdles even for incumbents.
The prescription segment dominated the market with a revenue share of 86.76% in 2024 due to rising demand for chronic disease treatments, technological advancements in drug development, and improved healthcare access. Favorable reimbursement policies, physician reliance on prescription medications, and increasing patient awareness contributed to this growth. Regulatory approvals, new product launches, and the expanding elderly population further boosted demand. In addition, the prevalence of lifestyle-related diseases and government initiatives promoting prescription drug use strengthened the segment’s position in the market. The rising occurrence of cancerhas been attributed to lifestyle changes in an increasingly geriatricpopulation in both developed countries and emerging economies. Environmentalfactors such as pollution and the high penetration of microplastics, apotential carcinogen, are also contributing to the growing number of cancercases.
Recent Developments In United States Pharmaceuticals Market
AI enables analysis of huge datasets in drug discovery to identify efficient drug candidates more quickly and effectively than conventional approaches, in the estimation of potential drugs’ targets, which will show raised efficiency, and is used in personalized treatment. Also, it has various applications in the selection of trial design in clinical trials, including the selection of the right subjects for a specific trial, real-time data, and anticipation of trial outcomes, etc. Overall, AI-powered technologies are time-consuming, cost-effective, and enhance outcomes are influencing the market expansion. The economic impact of prescription drugs is substantial and often a topic of discussion in healthcare policy. Prescription drug spending can be a significant portion of total healthcare expenditures for governments, insurance companies, and individuals. Based on type, the conventional drugs (small molecules) segment accounted for the largest revenue share of 54.74% in 2024, due to their well-established manufacturing process, predictable pharmacokinetics, and oral bioavailability.
